Faheem Hasnain Purchases 43,000 Shares of Tocagen Inc (NASDAQ:TOCA) Stock

Tocagen Inc (NASDAQ:TOCA) Director Faheem Hasnain bought 43,000 shares of the stock in a transaction on Thursday, May 30th. The shares were acquired at an average cost of $4.66 per share, for a total transaction of $200,380.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

TOCA stock traded up $0.09 during mid-day trading on Wednesday, reaching $6.43. 179,384 shares of the stock traded hands, compared to its average volume of 264,298. The company has a debt-to-equity ratio of 0.75, a current ratio of 5.05 and a quick ratio of 5.05. The stock has a 50-day simple moving average of $6.53. Tocagen Inc has a 52 week low of $4.13 and a 52 week high of $15.80. The company has a market cap of $139.36 million, a price-to-earnings ratio of -2.64 and a beta of 3.79.

Tocagen (NASDAQ:TOCA) last released its earnings results on Tuesday, May 7th. The company reported ($0.74) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.75) by $0.01. Tocagen had a negative net margin of 294.74% and a negative return on equity of 108.08%. The business had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $2.01 million. Sell-side analysts predict that Tocagen Inc will post -2.94 EPS for the current fiscal year.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Tocagen from a “buy” rating to a “hold” rating in a research report on Wednesday. Citigroup assumed coverage on shares of Tocagen in a research report on Thursday, May 30th. They set a “buy” rating on the stock. Leerink Swann set a $5.00 target price on shares of Tocagen and gave the stock a “hold” rating in a research report on Wednesday, May 22nd. Finally, Chardan Capital restated a “buy” rating and set a $10.00 price target on shares of Tocagen in a report on Wednesday, May 22nd. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $16.48.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA lifted its position in Tocagen by 72,350.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,347 shares of the company’s stock valued at $47,000 after acquiring an additional 4,341 shares in the last quarter. Stratos Wealth Partners LTD. increased its stake in Tocagen by 9.0% in the 4th quarter. Stratos Wealth Partners LTD. now owns 11,449 shares of the company’s stock valued at $94,000 after buying an additional 949 shares during the last quarter. Creative Planning acquired a new stake in Tocagen in the 1st quarter valued at $117,000. Bank of America Corp DE increased its stake in Tocagen by 28.6% in the 4th quarter. Bank of America Corp DE now owns 14,584 shares of the company’s stock valued at $120,000 after buying an additional 3,240 shares during the last quarter. Finally, Dowling & Yahnke LLC acquired a new stake in Tocagen in the 1st quarter valued at $132,000. Institutional investors and hedge funds own 34.88% of the company’s stock.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Featured Story: What causes a recession?

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply